Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Harmony Biosciences Holdings, Inc. - Common Stock (NQ: HRMY )

35.32 -3.77 (-9.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,145,497
Open 36.82
Bid (Size) 32.55 (1)
Ask (Size) 35.32 (3)
Prev. Close 39.09
Today's Range 35.01 - 37.05
52wk Range 28.14 - 41.61
Shares Outstanding 57,031,297
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Harmony Biosciences Stock Falls On FDA Setback For Pitolisant In Sleeping Disorder
Harmony Biosciences' FDA setback for pitolisant in idiopathic hypersomnia doesn't impact its 2025 revenue outlook, with a Phase 3 trial planned for late 2025. 
Via Benzinga
Exposures Product Safety
Harmony Biosciences Crashes On Surprise Rejection For Bread-And-Butter Drug
The agency rejected the drug in the application filing stage, which is earlier than usual. 
Via Investor's Business Daily

Performance

YTD
+1.41%
+1.41%
1 Month
-12.70%
-12.70%
3 Month
+8.74%
+8.74%
6 Month
-1.34%
-1.34%
1 Year
+6.97%
+6.97%

More News

Read More
Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia
From Harmony Biosciences Holdings, Inc.
Via Business Wire
While growth is established for NASDAQ:HRMY, the stock's valuation remains reasonable.
Via Chartmill
Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Harmony Biosciences Holdings, Inc.
Via Business Wire
Demystifying Harmony Biosciences: Insights From 5 Analyst Reviews
Via Benzinga
A Glimpse Into The Expert Outlook On Harmony Biosciences Through 7 Analysts
Via Benzinga
NASDAQ:HRMY, a growth stock which is not overvalued.
Via Chartmill
Friday's after hours session: top gainers and losers
Via Chartmill
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
NASDAQ:HRMY is not too expensive for the growth it is showing.
Via Chartmill
Analyst Expectations For Harmony Biosciences's Future
Via Benzinga
Earnings Outlook For Harmony Biosciences
Via Benzinga
Breaking Down Harmony Biosciences: 6 Analysts Share Their Views
Via Benzinga
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Via Investor's Business Daily
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
From Harmony Biosciences
Via Business Wire
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Via Chartmill
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Investors who lost money on Harmony Biosciences Holdings, Inc. should contact Levi & Korsinsky about an ongoing investigation - HRMY
Via ACCESSWIRE
Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
Via ACCESSWIRE
HRMY ALERT - Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
Via ACCESSWIRE
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Via Benzinga
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
Via Investor's Business Daily
Neurology-Focused Harmony Biosciences Gains Confidence With Wakix Sales Surge, Strategic Pipeline Expansion, Bullish Analyst Says
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.